Industry Sponsored Symposium: A New Treatment Era for Congenital Adrenal Hyperplasia: Androgen Management and Glucocorticoid Dose Reduction in Clinical Practice
October 1, 2025 I 12:00 – 1:00 PM MT (2pET)
Sponsored by: Neurocrine Biosciences
PROGRAM DESCRIPTION
This interactive, case-based presentation will provide an in-depth look at clinical data for a newly approved, non-glucocorticoid treatment for classic congenital adrenal hyperplasia (CAH) and will feature a clinical conversation about how to reduce glucocorticoids and manage androgens in real-world clinical practice. It will also provide a refresher on CAH pathophysiology and the impact of high androgens and chronic high dose glucocorticoid treatment in pediatric patients with CAH.
Learning objectives:
This interactive, case-based presentation will provide an in-depth look at clinical data for a newly approved, non-glucocorticoid treatment for classic congenital adrenal hyperplasia (CAH) and will feature a clinical conversation about how to reduce glucocorticoids and manage androgens in real-world clinical practice. It will also provide a refresher on CAH pathophysiology and the impact of high androgens and chronic high dose glucocorticoid treatment in pediatric patients with CAH.
CME credit will not be offered for this activity.
SPEAKERS:
- Natalie Nokoff, MD, PhD
Associate Professor, Department of Pediatric Endocrinology
Anschutz Medical Campus, Aurora, CO
Neurocrine Biosciences, Inc.